Jade Biosciences offers $135 million equity through private placement

* Jade Biosciences (NASDAQ:JBIO [https://seekingalpha.com/symbol/JBIO]) has entered into a private placement resulting in gross proceeds of approximately $135 million to the Company.
* The company is selling an aggregate of (i) 13,368,164 shares of its common stock at $9.14 per share and (ii) pre-funded warrants to purchase 1,402,092 shares of common stock at a price of $9.1399 per pre-funded warrant, with an exercise price of $0.0001 per share and may be exercised at any time after the date of issuance.
* Post transaction, there will be approximately 67.4 million shares of the company’s common stock and common stock equivalents issued and outstanding, including shares of common stock underlying pre-funded warrants and Series A non-voting convertible preferred stock. The PIPE financing is expected to close on or about October 8th, 2025.
* The net proceeds will be used for the PIPE financing, together with its existing cash, cash equivalents, and marketable securities, to fund research and development, general corporate expenses, and working capital needs.
* Based on current operating plans, the Company expects that its cash, cash equivalents, and marketable securities will fund operations into the first half of 2028.
* JBIO +24.8% premarket to $11.41
* Source: Press Release [https://seekingalpha.com/pr/20256602-jade-biosciences-announces-135-million-private-placement]

MORE ON JADE BIOSCIENCES, INC.

* Jade Biosciences, Inc. GAAP EPS of -$0.86 [https://seekingalpha.com/news/4485034-jade-biosciences-inc-gaap-eps-of-0_86]
* Historical earnings data for Jade Biosciences, Inc. [https://seekingalpha.com/symbol/JBIO/earnings]
* Dividend scorecard for Jade Biosciences, Inc. [https://seekingalpha.com/symbol/JBIO/dividends/scorecard]
* Financial information for Jade Biosciences, Inc. [https://seekingalpha.com/symbol/JBIO/income-statement]